8-K: Tempus AI Reports Strong Q1 2026 Results, Raises Guidance

Tempus AI announced first quarter 2026 financial results, showcasing significant year-over-year revenue growth and increased financial guidance for the full year.

Summary

• Tempus AI reported first quarter 2026 revenue of $348.1 million, a 36.1% increase year-over-year.
• Diagnostics revenue grew by 34.7% to $261.1 million, with Oncology volume up 28% and MRD volume up approximately 500%.
• Data and Applications revenue increased by 40.5% to $87.0 million, with Insights growing 44.1%.
• Gross profit rose 43.1% to $222.0 million.
• Net loss was $125.9 million, compared to $68.0 million in Q1 2025.
• Adjusted EBITDA improved to a loss of $2.8 million, from a loss of $16.2 million in Q1 2025.
• The company raised its full-year 2026 revenue guidance to $1.59 billion - $1.60 billion.
• Full-year 2026 Adjusted EBITDA is expected to be approximately $65 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved operational metrics, and raised guidance, despite a continued net loss.

Positives

• Revenue increased by 36.1% year-over-year to $348.1 million.
• Diagnostics revenue grew 34.7% year-over-year, driven by Oncology volume growth of 28% and Hereditary volume growth of 54%.
• MRD volume saw a significant increase of approximately 500% year-over-year.
• Data and Applications revenue grew 40.5% year-over-year, with Insights growing 44.1%.
• Gross profit increased 43.1% year-over-year to $222.0 million.
• Adjusted EBITDA improved significantly, narrowing the loss to $2.8 million from $16.2 million in the prior year.
• Full-year 2026 revenue guidance was increased to $1.59 billion - $1.60 billion, representing approximately 25% annual growth.
• The company has $643.8 million in cash and marketable securities as of March 31, 2026.

Negatives

• Net loss widened to $125.9 million in Q1 2026, compared to $68.0 million in Q1 2025.
• The company reported a loss from operations of $84.7 million, an increase from $68.7 million in the prior year.
• Non-GAAP loss from operations was $11.6 million, an increase from $25.8 million in the prior year.
• Non-GAAP net loss was $22.6 million, compared to $41.6 million in the prior year, indicating continued operational losses on a non-GAAP basis.
• Stock-based compensation expense was $52.7 million, a significant increase from $23.0 million in the prior year, contributing to the net loss.

Risks

• The company faces risks related to the intended use of its products and services.
• Competition and new market entrants pose a risk to market share and pricing.
• Compliance with new laws, regulations, and executive actions, including evolving AI regulations, presents a risk.
• The ability to maintain, protect, and enhance intellectual property is a key risk.
• Attracting and retaining qualified team members and key personnel is crucial.
• The ability to repay or refinance outstanding debt, or access additional financing, is a potential risk.
• Future acquisitions, divestitures, or investments carry inherent risks, including realizing expected benefits.
• The potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions, and war are listed as risks.

Future Outlook

Tempus AI is increasing its full-year 2026 revenue guidance to a range of $1.59 billion to $1.60 billion, representing approximately 25% annual growth. The company continues to expect full-year 2026 Adjusted EBITDA to be approximately $65 million.

Management Comments

• "Our strong financial and operational performance this quarter underscores the accelerating demand for our AI-driven diagnostic platform and the immense value of our multimodal data and corresponding AI models," said Eric Lefkofsky, Founder and CEO of Tempus.
• "We continue to see strong momentum as we deploy more sophisticated algorithms across our platform, driving 36% revenue growth year-over-year, with particular strength in our Oncology diagnostic business and data and modeling business."

Industry Context

StockSavvy.ai notes that Tempus AI's strong Q1 2026 performance, with significant revenue growth in both diagnostics and data/applications, aligns with the broader industry trend of increasing adoption of AI and data-driven solutions in precision medicine. The company's strategic collaborations with major pharmaceutical and healthcare providers highlight its expanding influence and the growing recognition of its platform's value in accelerating drug discovery and improving patient care.

Comparison to Industry Standards

• Tempus AI's revenue growth of 36.1% in Q1 2026 significantly outpaces the average growth rates seen in many segments of the healthcare technology and diagnostics industries, which often experience single to low double-digit growth.
• The company's MRD volume growth of approximately 500% is exceptional and suggests a rapid market penetration and adoption of this specific diagnostic technology, far exceeding typical market expansion rates.
• While Tempus AI is still operating at a net loss, the improvement in Adjusted EBITDA from -$16.2 million to -$2.8 million indicates a positive trend towards profitability, which is a key focus for many growth-stage companies in the AI and biotech sectors.
• The company's strategic collaborations with Merck and Gilead are significant, as these are major players in the pharmaceutical industry. Such partnerships are often benchmarks for validating a company's technology and market position within the competitive landscape of drug discovery and development.

Related Party Transactions

• Includes related party revenue of $21,823 thousand for the three months ended March 31, 2026.
• Includes related party accounts receivable of $15,690 thousand as of March 31, 2026.
• Includes related party deferred revenue of $403 thousand as of March 31, 2026.

Stakeholder Impact

• Shareholders: Positive impact from increased revenue guidance and improved operational efficiency, potentially leading to future value appreciation.
• Employees: Continued growth and investment in AI and R&D may lead to job creation and opportunities, but also potential pressure from stock-based compensation expenses.
• Customers: Access to advanced AI-driven diagnostic tools and data insights for personalized patient care and drug development.
• Partners (Merck, Gilead, Northwestern Medicine, NYU Langone Health): Strengthened collaborations to advance precision medicine and oncology research.

Next Steps

• Host conference call and webcast on May 5, 2026, after market close.
• Host inaugural Investor Day on May 29, 2026.
• Continue to deploy sophisticated algorithms across the platform.
• Leverage multimodal data and AI models to drive growth in diagnostics and data licensing.

Key Dates

Recommendation

The company demonstrated robust top-line growth, significant improvements in operational efficiency as evidenced by the narrowed Adjusted EBITDA loss, and raised its full-year guidance. These factors, combined with strategic partnerships and strong market adoption of its AI-driven diagnostic tools, suggest a positive trajectory and strong potential for future value creation, warranting a strong buy recommendation.

Keywords

Tempus AI, Precision Medicine, AI Diagnostics, Oncology, Data Licensing, Biomarker Discovery, Healthcare Technology, Financial Results